Safety of pembrolizumab in combination with bevacizumab in recurrent glioblastoma (rGBM).

被引：13
|
作者：
Reardon, David A.
De Groot, John Frederick
Colman, Howard
Jordan, Justin T.
Daras, Mariza
Clarke, Jennifer Leigh
Nghiemphu, Phioanh Leia
Gaffey, Sarah C.
Peters, Katherine B.
机构：
[1] Harvard Canc Ctr, Dana Farber Canc Inst, Boston, MA USA
[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[3] Hunstman Canc Inst Utah, Salt Lake City, UT USA
[4] Massachusetts Gen Hosp, Boston, MA 02114 USA
[5] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[6] Univ Calif San Francisco, San Francisco, CA 94143 USA
[7] Univ Calif Los Angeles, Los Angeles, CA USA
[8] Dana Farber Canc Inst, Boston, MA 02115 USA
[9] Duke Univ, Med Ctr, Durham, NC USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.2010
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2010
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
    Omar, Ayman I.
    JOVE-JOURNAL OF VISUALIZED EXPERIMENTS, 2014, (92):
  • [22] RANDOMIZED PHASE 2 STUDY OF NIVOLUMAB (NIVO) PLUS EITHER STANDARD OR REDUCED DOSE BEVACIZUMAB (BEV) IN RECURRENT GLIOBLASTOMA (RGBM)
    Ahluwalia, Manmeet
    Peereboom, David
    Rauf, Yasmeen
    Lathia, Justin
    Alban, Tyler
    Schilero, Cathy
    Ciolfi, Marci
    LaForest-Roys, Corey
    Nayak, Lakshmi
    Lee, Eudocia
    Wen, Patrick
    Reardon, David
    NEURO-ONCOLOGY, 2020, 22 : 35 - 35
  • [23] Clinical activity and safety of sintilimab, bevacizumab, and TMZ in patients with recurrent glioblastoma
    Lu, Yinghao
    Liao, Limin
    Du, Kunpeng
    Mo, Jianhua
    Zou, Xia
    Liang, Junxian
    Chen, Jiahui
    Tang, Wenwen
    Su, Liwei
    Wu, Jieping
    Zhang, Junde
    Tan, Yujing
    BMC CANCER, 2024, 24 (01)
  • [24] Clinical activity and safety of sintilimab, bevacizumab, and TMZ in patients with recurrent glioblastoma
    Yinghao Lu
    Limin Liao
    Kunpeng Du
    Jianhua Mo
    Xia Zou
    Junxian Liang
    Jiahui Chen
    Wenwen Tang
    Liwei Su
    Jieping Wu
    Junde Zhang
    Yujing Tan
    BMC Cancer, 24
  • [25] Bevacizumab in recurrent glioblastoma multiforme
    Tayah, Tania
    Ashrafieh
    Chahine, Georges Y.
    Kamar, Francois G.
    NEUROLOGY, 2008, 70 (11) : A296 - A297
  • [26] Efficacy and safety study of fotemustine and bevacizumab in patients with recurrent glioblastoma.
    Escudero, Laura Sanchez
    Urbano, Maria Amor
    Garces, Maria Yeray Rodriguez
    Murillo, Fatima Toscano
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [27] Bevacizumab for the Treatment of Recurrent Glioblastoma
    Chamberlain, Marc C.
    CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2011, 5 : 117 - 129
  • [28] EFFICACY AND SAFETY OF BEVACIZUMAB COMBINATION CHEMOTHERAPY FOR RECURRENT CERVICAL CANCER
    Kusakabe, M.
    Tanikawa, M.
    Oda, K.
    Nagasaka, K.
    Miyamoto, Y.
    Sone, K.
    Mori, M.
    Tsuruga, T.
    Matsumoto, Y.
    Osuga, Y.
    Fujii, T.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2018, 28 : 318 - 318
  • [29] ACTIVITY AND SAFETY OF THE COMBINATION BEVACIZUMAB AND FOTEMUSTINE IN RECURRENT MALIGNANT GLIOMAS
    Fabi, Alessandra
    Villani, Veronica
    Vaccaro, Vanja
    Vidiri, Antonello
    Giannarelli, Diana
    Piludu, Francesca
    Anelli, Vincenzo
    Carapella, Carmine
    Cognetti, Francesco
    Pace, Andandrea
    NEURO-ONCOLOGY, 2013, 15 : 108 - 108
  • [30] Ombipepimut dosing emulsion (ODE) plus bevacizumab (bev) vs bev alone in patients (pts) with recurrent or progressive glioblastoma (rGBM)
    Goldlust, Samuel Aaron
    Chang, Jong Hee
    Narita, Yoshitaka
    Welch, Mary Roberta
    Green, Richard M.
    Drappatz, Jan
    Piccioni, David Eric
    Kim, Yu Jung
    Melear, Jason M.
    Tanaka, Shota
    Wei, Kuo-Chen
    Fink, Karen L.
    Pitz, Marshall W.
    Cloughesy, Timothy Francis
    De Groot, John Frederick
    McClellan, Nanci
    Hitron, Matthew
    Xu, Bo
    Jin, Bo
    Lebedinsky, Claudia
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345